Danilon Equidos 1.5g Granules are non-steroidal anti-inflammatory drugs for the treatment of pain and inflammation associated with musculoskeletal conditions in the horse, such as bursitis, laminitis and degenerative joint diseases. Commonly referred to as osteoarthritis, a degenerative joint disease, it is a progressive, long-lasting amazing cartilage surrounding the joints that cause stiffness.
Danilon Equidos 1.5g Granules is an easy-to-use oral medicine that effectively helps to relieve pain and inflammation in horses. If you have access to veterinary surgeons affecting the active substance, Suxibuzone, the production of tissue relaxation hormones that have anti-inflammatory and analgesic effects. With possible bag options Danilon may be used in the treatment of postoperative pain with soft tissue and orthopedic surgery in horses.
Danilon Equidos 1.5g Granules are manufactured by Elanco and developed specifically for horses. Therefore, this could never choose legal animals. During treatment of very young animals (less than 12 weeks) where development of their hepatic or renal function may be incomplete, or in aged animals which may have these functions impaired, as well as in ponies, the additional risk may be involved. In these cases, doses should be accurately calculated and patients monitored closely.
For a 480 kg bodyweight horse, the contents of 2 sachets should be administered twice daily (equivalent to 12.5 mg of suxibuzone/kg/day) for 2 days, followed by 1 sachet twice daily (6.25 mg of suxibuzone/kg/day) for 3 days. Thereafter, 1 sachet daily (3.1 mg of suxibuzone/kg/day) or on alternate days, or the minimum dose necessary for a satisfactory clinical response.
Ponies should receive only half the dose rate recommended for horses. For a 240 kg bodyweight pony, the contents of 1 sachet should be administered daily (equivalent to 6.25 mg of suxibuzone/kg/day) for 2 days, followed by 1/2 sachet daily (3.1 mg of suxibuzone/kg/day) for 3 days or 1 sachet on alternate days. Thereafter, reduce the dose to the minimum dose necessary for a satisfactory clinical response.